Peter Ntiamoah
Research Subjects
Peter Ntiamoah has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Christine Iacobuzio-Donahue
The David M Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY
24 shared publications - Henry Walch
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
24 shared publications - Andrew L. Kung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
16 shared publications - Andrika D. Thomas
Memorial Sloan Kettering Cancer Center 1 New York, NY
16 shared publications - Armaan Siddiquee
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
16 shared publications - Audrey Mauguen
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
16 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Optimization efforts to procure patient tumors, establish PDX tumor models and cryopreserve PDX tumor specimen.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Optimization efforts to procure patient tumors, establish PDX tumor models and cryopreserve PDX tumor specimen.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Comparative analysis of mutations in patient source tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Comparative analysis of mutations in patient source tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Validation of a EPB41L2::RAF1 gene fusion in an osteosarcoma PDX model.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Validation of a EPB41L2::RAF1 gene fusion in an osteosarcoma PDX model.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Evaluation of the EPB41L2::RAF1 gene fusion as an oncogenic driver and therapeutic target in osteosarcoma PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Evaluation of the EPB41L2::RAF1 gene fusion as an oncogenic driver and therapeutic target in osteosarcoma PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of sarcoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of sarcoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of osteosarcoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of osteosarcoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of neuroblastoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of neuroblastoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of Other Tumor cohort and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of Other Tumor cohort and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Molecular characterization of sarcoma PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Molecular characterization of sarcoma PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Molecular characterization of neuroblastoma PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Molecular characterization of neuroblastoma PDX models.